Acamprosate
Campral (acamprosate) is a small molecule pharmaceutical. Acamprosate was first approved as Campral on 2004-07-29. It is used to treat alcoholism in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| chemically-induced disorders | D064419 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acamprosate calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAMPRAL | Forest Laboratories | N-021431 DISCN | 2004-07-29 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acamprosate calcium | ANDA | 2023-11-06 |
| campral | New Drug Application | 2016-08-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcoholism | EFO_0003829 | D000437 | F10.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 7 | 3 | 12 | 4 | 26 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | 1 | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | 1 | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | 1 | — | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | — | 1 | — | 2 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | — | 1 |
| Gambling | D005715 | EFO_1001926 | F63.0 | — | — | — | 1 | — | 1 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fragile x syndrome | D005600 | — | Q99.2 | 2 | 1 | — | — | — | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
| Alcohol-related disorders | D019973 | — | F10 | — | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | 1 | — | — | — | 1 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | — | — | — | 1 |
| Tardive dyskinesia | D000071057 | — | G24.01 | — | 1 | — | — | — | 1 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 1 | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tinnitus | D014012 | HP_0000360 | H93.1 | 1 | — | — | — | — | 1 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Acamprosate |
| INN | acamprosate |
| Description | Acamprosate calcium is an organic calcium salt. It contains an acamprosate(1-). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)NCCCS(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 77337-76-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201293 |
| ChEBI ID | 51041 |
| PubChem CID | 155434 |
| DrugBank | DB00659 |
| UNII ID | N4K14YGM3J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Acamprosate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,477 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
867 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use